December 28 2006

First human study with vasopharm's trauma compound VAS203

vasopharm has received a positive ethics vote for the first study in humans of VAS203

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, announced today that the company has received a positive ethics vote from the Landesärztekammer Baden-Württemberg, Stuttgart, Germany and the necessary approval from the Federal Institute for Drugs and Medical Devices, Germany (BfArM) for the first study in humans of VAS203.

The goal of the upcoming phase I study which will start in January 2007 is to demonstrate safety, tolerability and pharmacokinetics of ascending single intravenous administrations of VAS203 in healthy volunteers. Provided that the enrolment of the volunteers proceeds as intended the results of the study are expected in June 2007. The single dose administration study will then be followed by a multiple dose study which is currently planned for July 2007.